On this page
Biotinidase deficiency
Also known as Biotinidase deficiency (profound) · Biotinidase deficiency (partial) · Biotinidase deficiency (hearing loss)
This condition prevents the body from reusing biotin, which is crucial for certain enzymes. It can lead to neurological and skin issues if untreated, and is typically identified through newborn screening in the UK.
Available at Jeen Health
Clinical tests that include this
Overview
Biotinidase deficiency is a rare inherited metabolic disorder that affects how the body processes the vitamin biotin. Biotin is essential for the function of several enzymes called carboxylases, which play important roles in breaking down fats, proteins, and carbohydrates in the body. In individuals with biotinidase deficiency, the enzyme biotinidase does not function correctly, leading to a shortage of available biotin for these crucial processes [PMID:17929223]. This can result in a range of health problems if not identified and managed.
Biotinidase deficiency is generally categorised into two forms: profound and partial. Profound deficiency means very little or no biotinidase activity, while partial deficiency indicates some reduced activity. The severity of the condition often correlates with the level of enzyme activity. Early diagnosis, typically through newborn screening programmes in the UK, allows for straightforward and effective treatment, preventing severe complications.
Symptoms & clinical features
The symptoms of biotinidase deficiency can vary significantly between individuals and often depend on whether the deficiency is profound or partial, and if treatment has not been initiated. For those with profound deficiency who are not treated, symptoms often appear within the first few months of life, though they can emerge later [PMID:19602283]. These may include neurological issues such as seizures, developmental delay, and problems with muscle tone (hypotonia).
Other potential signs can involve skin rashes (eczema-like), hair loss (alopecia), and breathing difficulties. Vision problems and hearing loss can also occur. In partial biotinidase deficiency, symptoms may be milder or appear later, sometimes only during periods of stress or illness. With early identification and treatment, many of these symptoms can be prevented or significantly reduced [PMID:19602283].
Video: Genetics 101
Affected organs
Biotinidase deficiency primarily affects organs and systems that rely heavily on biotin-dependent enzymes for their normal function. The nervous system is commonly impacted, leading to potential issues with the brain and nerves, such as developmental delays, seizures, and problems with coordination and balance. Sensory organs, including the eyes and ears, can also be affected, potentially causing vision impairment and hearing loss.
The skin is another area often involved, with individuals sometimes developing characteristic rashes and experiencing hair loss. The immune system may also be compromised in some cases, potentially leading to increased susceptibility to infections. Without appropriate treatment, multiple organ systems can be affected, highlighting the importance of early intervention.
Risks & severity
The severity of biotinidase deficiency is directly related to the residual activity of the biotinidase enzyme. Profound deficiency, with less than 10% of normal enzyme activity, typically leads to more severe symptoms if untreated, potentially causing significant neurological damage, developmental delay, and even life-threatening metabolic crises [PMID:17929223]. Partial deficiency, with 10-30% of normal enzyme activity, often results in milder or later-onset symptoms, which may only become apparent during times of physiological stress like illness.
With early diagnosis, usually through the NHS newborn screening programme, and lifelong treatment, the risks of developing severe complications are substantially reduced. The long-term outlook for individuals who receive early and consistent treatment is generally excellent, with most living healthy lives with typical development. Untreated profound biotinidase deficiency, however, carries a significant risk of severe, irreversible neurological damage and other systemic problems.
Genetic causes
Biotinidase deficiency is caused by pathogenic variants in the BTD gene. The BTD gene provides instructions for making the biotinidase enzyme. This enzyme plays a crucial role in recycling biotin, a B vitamin, from both dietary sources and within the body [PMID:19602283]. Biotinidase releases biotin from proteins so it can be reused by other enzymes, specifically a group known as carboxylases.
These biotin-dependent carboxylases are vital for several metabolic processes, including the breakdown of fats, proteins, and carbohydrates for energy. When pathogenic variants occur in the BTD gene, the biotinidase enzyme either isn't produced at all or doesn't function correctly. This leads to a build-up of biotin that is 'locked' to proteins and cannot be recycled, resulting in a functional biotin deficiency for the carboxylases, which then cannot perform their roles effectively [PMID:17929223].
- BTD biotinidaseThe BTD gene provides instructions for the biotinidase enzyme, which is crucial for recycling the B vitamin biotin, enabling its reuse in various metabolic processes.
Inheritance pattern
Biotinidase deficiency is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the altered BTD gene - one from each parent - to develop the condition. If a person inherits only one copy of the altered gene, they are considered a carrier. Carriers typically do not show symptoms of the condition themselves because their single functional copy of the BTD gene produces enough biotinidase enzyme.
When two carriers have children, there is a 25% (1 in 4) chance with each pregnancy that the child will inherit two altered copies of the gene and develop biotinidase deficiency. There is a 50% (2 in 4) chance the child will be a carrier like their parents, and a 25% (1 in 4) chance the child will inherit two normal copies of the gene and neither have the condition nor be a carrier. Genetic counselling can provide detailed information and support for families regarding inheritance patterns and risks.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Subtypes & variants
This page covers Biotinidase deficiency as a single condition. Several distinct variants and clinical subtypes are recognised in the literature - they share the underlying biology and broad management approach, but differ in severity, age of onset, or causative gene:
- Profound (<10% activity) OMIM 253260
Less than 10 per cent of normal biotinidase activity. Without treatment, presents in infancy with seizures, hypotonia, eczema, and hearing loss. Treated with lifelong biotin supplementation; outcomes are excellent if started early.
- Partial (10–30% activity) OMIM 253260
10 to 30 per cent of normal biotinidase activity. Symptoms are milder and may only emerge during illness or stress. Biotin supplementation prevents progression.
- With hearing loss OMIM 253260
Sensorineural hearing loss is a recognised long-term complication of untreated profound biotinidase deficiency, particularly when treatment is started after the newborn period.
Diagnosis & testing
In the UK, biotinidase deficiency is primarily diagnosed through the NHS Newborn Blood Spot Screening Programme. This screening test, typically performed a few days after birth, measures the activity of the biotinidase enzyme in a small blood sample [PMID:28774706]. If the screening indicates low enzyme activity, further diagnostic tests are carried out, usually involving repeat enzyme assays and sometimes genetic testing for variants in the BTD gene, to confirm the diagnosis and determine if it is profound or partial.
For individuals not screened as newborns, diagnosis might occur later in life if symptoms appear. In such cases, a clinical geneticist or metabolic specialist would typically refer for biochemical tests to measure biotinidase activity in blood. Genetic testing (NHS R-code R14) can then confirm the BTD gene variant(s) responsible. Referral to clinical genetics services can be made by a GP or other healthcare professional if there is a suspicion of an inherited metabolic disorder.
Management & lifestyle
The primary management for biotinidase deficiency, once diagnosed, is lifelong oral supplementation with biotin. This simple and highly effective treatment provides the body with enough free biotin to bypass the need for the faulty biotinidase enzyme, allowing the biotin-dependent carboxylases to function correctly [PMID:19602283]. The dose of biotin varies depending on whether the deficiency is profound or partial, and will be determined by a metabolic specialist.
Regular follow-up appointments with a metabolic team are crucial to monitor treatment effectiveness, assess development, and adjust biotin dosage as needed. Adherence to biotin supplementation is essential to prevent the onset or progression of symptoms. Genetic counselling is also an important part of the management pathway, offering support and information to affected individuals and their families regarding the condition and its inheritance.
UK care pathway
In the UK, the care pathway for biotinidase deficiency typically begins with the NHS Newborn Blood Spot Screening Programme. If a baby screens positive, they are promptly referred to a specialist metabolic team, often based in a regional paediatric hospital. This team includes metabolic consultants, specialist nurses, and dietitians who will confirm the diagnosis and initiate treatment. Genetic testing, typically under NHS R-code R14, can confirm the underlying genetic cause.
Lifelong management involves regular monitoring by this specialist team. Genetic counsellors are available to provide comprehensive information about the condition's inheritance, implications for family planning, and support for the wider family. This integrated approach ensures that individuals receive timely diagnosis and ongoing care aligned with NHS Genomic Medicine Service principles.
Frequently asked questions
What is biotin and why is it important?
Biotin is a B vitamin that is crucial for the function of several enzymes in the body. These enzymes are vital for breaking down fats, proteins, and carbohydrates, which are essential processes for energy production and overall health.
Can biotinidase deficiency be cured?
Biotinidase deficiency is a lifelong condition, but it is effectively managed with daily oral biotin supplements. Taking biotin supplements consistently allows individuals to lead healthy lives and prevents the development of severe symptoms, effectively 'treating' the functional deficiency.
How is biotinidase deficiency detected in newborns?
In the UK, biotinidase deficiency is part of the routine NHS Newborn Blood Spot Screening Programme. A small blood sample is taken from the baby's heel a few days after birth and tested for biotinidase enzyme activity. Low activity prompts further investigation.
What happens if biotinidase deficiency is not treated?
Without treatment, profound biotinidase deficiency can lead to serious health problems, including seizures, developmental delay, hearing loss, vision problems, skin rashes, and hair loss. Early diagnosis and treatment are crucial to prevent these complications.
Are there different types of biotinidase deficiency?
Yes, there are typically two forms: profound and partial. Profound deficiency means very low or no enzyme activity, leading to more severe symptoms if untreated. Partial deficiency means some reduced enzyme activity, often resulting in milder or later-onset symptoms.
References
- Woodliff B, Benjamin R, Simpson B. Biotinidase Deficiency. 2025. PMID: 32809442
- Winchester S, Singh PK, Mikati MA. Ataxia. Handbook of clinical neurology. 2013. PMID: 23622331
- Karachaliou CE, Livaniou E. Biotin Homeostasis and Human Disorders: Recent Findings and Perspectives. International journal of molecular sciences. 2024. PMID: 38928282
- Wolf B, Heard GS. Biotinidase deficiency. Advances in pediatrics. 1991. PMID: 1927696
- Sharma R, Kucera CR, Nery CR. Biotinidase biochemical and molecular analyses: Experience at a large reference laboratory. Pediatrics international : official journal of the Japan Pediatric Society. 2024. PMID: 38299772
- Adam MP, Bick S, Mirzaa GM. Biotinidase Deficiency. 1993. PMID: 20301497
- Wolf B, Heard GS, McVoy JR. Biotinidase deficiency. Annals of the New York Academy of Sciences. 1985. PMID: 3925856
- Biswas A, McNamara C, Gowda VK. Neuroimaging Features of Biotinidase Deficiency. AJNR. American journal of neuroradiology. 2023. PMID: 36759144